A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status

Introduction: The evidence for remdesivir therapy in immunocompromised patients is scarce. To evaluate remdesivir (RDV) effectiveness and safety in COVID-19 outpatients at high risk for progression in a real-world setting, we compare the outcome in immunocompromised (IC) patients with that in non-im...

Full description

Bibliographic Details
Main Authors: José Manuel Ramos-Rincón, Héctor Pinargote-Celorio, Jara Llenas-García, Oscar Moreno-Pérez, Inmaculada González-Cuello, Pilar Gonzalez-de-la-Aleja, Belén Martínez-López, Sergio Reus, María García-López, Juan Carlos Rodríguez, Vicente Boix, Esperanza Merino
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
SARS-CoV-2 early treatment
remdesivir
outpatient SARS-CoV-2 treatment
immunosupressed SARS-CoV2 treatment
hospitalization SARS-CoV-2 infection
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1218650/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1218650/full

Similar Items